# A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

> **NCT02766699** · PHASE1 · COMPLETED · sponsor: **Engeneic Pty Limited** · enrollment: 9 (actual)

## Conditions studied

- Glioblastoma
- Astrocytoma, Grade IV

## Interventions

- **DRUG:** EGFR(V)-EDV-Dox

## Key facts

- **NCT ID:** NCT02766699
- **Lead sponsor:** Engeneic Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-25
- **Primary completion:** 2021-08-21
- **Final completion:** 2022-03-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02766699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02766699, "A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02766699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*